Clinical Trials
3
Active:0
Completed:2
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects
Phase 1
Recruiting
- Conditions
- HypertriglyceridemiaFamilial Chylomicronemia Syndrome
- Interventions
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Ikaria Bioscience Pty Ltd
- Target Recruit Count
- 108
- Registration Number
- NCT06471543
- Locations
- 🇺🇸
Lifeline Primary Care/Avacare, Lilburn, Georgia, United States
🇺🇸Versailles Family Medicine / Avacare, Versailles, Kentucky, United States
🇺🇸Axis Clinicals USA, Dilworth, Minnesota, United States
the Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects in Adult Subjects With Elevated LDL-C
Phase 1
Completed
- Conditions
- To Reduce the LDL-C Level in Hypercholesteremia Patients
- Interventions
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Shanghai Rona Therapeutics Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06132360
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
Adult Subjects With Elevated Low-Density Lipoprotein-Cholesterol to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects
Phase 1
Completed
- Conditions
- To Reduce the LDL-C Level in Hypercholesteremia Adult PatientsCombination for Subgroup High LDL-c Patients With Other Comorbidities
- Interventions
- Drug: RN0191 INJECTION
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Ikaria Bioscience Pty Ltd
- Target Recruit Count
- 32
- Registration Number
- NCT05905068
- Locations
- 🇦🇺
Nucleus Networks, Herston, Brisbane, Australia
News
No news found